Literature DB >> 36186224

Eosinophilic cystitis mimicking hemorrhagic cystitis in relapsed follicular lymphoma.

Toshiaki Nagaie1, Kazuharu Kamachi1,2, Hiroaki Kitamura1, Hiroshi Ureshino2, Michiaki Akashi3, Kazushige Nishimura4, Hiroyuki Meiri5, Shinya Kimura2, Masaharu Miyahara1.   

Abstract

Eosinophilic cystitis (EC) is a rare and non-infectious inflammatory disorder characterized by transmural infiltration of eosinophils in the bladder wall. The diagnosis of EC is made only by the pathophysiological findings. Because the urinary symptoms of EC are quite similar to other urinary tract disorders including hemorrhagic cystitis (HC), it can be misdiagnosed or left undiagnosed. A 49-year-old woman with relapsed and refractory follicular lymphoma presented with sudden-onset gross hematuria after the chemo-immunotherapy. The patient was initially treated as HC with continuous bladder irrigation, resulting in recurrent and refractory hematuria. Corticosteroid dramatically resolved hematuria after the bladder biopsy revealed EC. It is important to suspect EC and perform bladder biopsy in patients with recurrent episodes of hematuria or refractory to conservative treatment for HC.
© The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 2022.

Entities:  

Keywords:  Corticosteroids; Eosinophilic cystitis; Follicular lymphoma; Hemorrhagic cystitis

Year:  2022        PMID: 36186224      PMCID: PMC9522950          DOI: 10.1007/s13691-022-00565-8

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  12 in total

1.  Adenovirus infections in transplant recipients.

Authors:  Michael G Ison
Journal:  Clin Infect Dis       Date:  2006-06-19       Impact factor: 9.079

2.  Eosinophilic cystitis following cord blood transplantation: a form of acute GVHD. A variant of hemorrhagic cystitis after hematopoietic SCT or drug-induced?

Authors:  T Tasaka; Y Matsuhashi; H Ohnishi; Y Kubota
Journal:  Bone Marrow Transplant       Date:  2008-07-07       Impact factor: 5.483

Review 3.  BK and JC virus: a review.

Authors:  Michelle Pinto; Simon Dobson
Journal:  J Infect       Date:  2013-10-08       Impact factor: 6.072

4.  Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy.

Authors:  Akiko Miyagi Maeshima; Hirokazu Taniguchi; Takahiro Fujino; Yo Saito; Yuta Ito; Shunsuke Hatta; Sayako Yuda; Shinichi Makita; Suguru Fukuhara; Wataru Munakata; Tatsuya Suzuki; Dai Maruyama; Koji Izutsu
Journal:  Ann Hematol       Date:  2020-05-26       Impact factor: 3.673

Review 5.  Mechanisms of hemorrhagic cystitis.

Authors:  Subhash Haldar; Christopher Dru; Neil A Bhowmick
Journal:  Am J Clin Exp Urol       Date:  2014-10-02

Review 6.  Eosinophilic cystitis in adults.

Authors:  N M Itano; R S Malek
Journal:  J Urol       Date:  2001-03       Impact factor: 7.450

7.  [Clinical study of eosinophilic cystitis. I. On the definition of eosinophilic cystitis. I-1. Histological observation of eosinophilic infiltration].

Authors:  T Yamada; H Taguchi
Journal:  Hinyokika Kiyo       Date:  1984-12

Review 8.  Male predominance among Japanese adult patients with late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation.

Authors:  Y Asano; Y Kanda; N Ogawa; M Sakata-Yanagimoto; M Nakagawa; M Kawazu; S Goyama; K Kandabashi; K Izutsu; Y Imai; A Hangaishi; M Kurokawa; S Tsujino; S Ogawa; K Aoki; S Chiba; T Motokura; H Hirai
Journal:  Bone Marrow Transplant       Date:  2003-12       Impact factor: 5.483

Review 9.  The spectrum of eosinophilic cystitis in males: case series and literature review.

Authors:  Oana-Eugenia Popescu; Steve K Landas; Gabriel P Haas
Journal:  Arch Pathol Lab Med       Date:  2009-02       Impact factor: 5.534

Review 10.  Rituximab for refractory eosinophilic fasciitis: a case series with long-term follow-up and literature review.

Authors:  Nikolaos Kougkas; George Bertsias; Ioannis Papalopoulos; Argiro Repa; Prodromos Sidiropoulos; Nestor Avgoustidis
Journal:  Rheumatol Int       Date:  2021-05-19       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.